Sana Biotechnology SANA Income Statement (2020-2026)

NASDAQ SANA
$3.85 -0.07 (-1.79%)
As of: Sep 4, 2026 · 3:59 PM EDT
Reported Financials

Sana Biotechnology Quarterly Income Statement

Periods 26 quarters
Latest Jun 2026

Sana Biotechnology reported net income of -$63.70M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
182.91M184.93M186.63M188.43M189.90M191.02M191.41M196.88M197.06M197.86M221.29M222.21M223.11M223.92M225.46M230.51M262.26M266.73M269.82M299.31M
Operating items
Research & DevelopmentR&D
53.24M108.50M72.69M72.54M76.73M63.92M67.17M73.04M65.61M7.00M56.45M60.87M53.21M1.90M37.19M29.76M30.11M34.92M28.72M30.73M
Selling, General & AdministrativeSG&A
13.43M12.68M14.43M18.29M15.51M23.32M16.77M16.57M19.18M20.78M16.27M16.44M14.05M17.28M11.48M10.34M10.29M12.19M11.46M10.78M
Other Operating ExpensesOther Opex
16.75M-9.90M-55.44M-17.93M-6.06M-5.45M0.12M26.68M-82.61M62.84M38.01M-27.94M-5.50M31.69M1.96M54.87M3.12M14.09M8.43M23.91M
Operating ExpensesOpex
83.43M111.28M31.68M72.90M86.19M81.79M84.05M116.29M2.18M90.62M110.72M49.37M61.76M50.87M50.63M94.97M43.52M61.20M48.61M65.42M
Operating IncomeOp. Inc
-83.43M-111.28M-31.68M-72.90M-86.19M-81.79M-84.05M-116.29M-2.18M-90.62M-110.72M-49.37M-61.76M-50.87M-50.63M-94.97M-43.52M-61.20M-48.61M-65.42M
EBIT
-83.43M-111.28M-31.68M-72.90M-86.19M-81.79M-84.05M-116.29M-2.18M-90.62M-110.72M-49.37M-61.76M-50.87M-50.63M-94.97M-43.52M-61.20M-48.61M-65.42M
Non-operating items
Interest & Investment IncomeInt & Inv Inc
0.16M-1.80M-3.81M-1.18M1.17M8.81M2.19M2.37M2.86M2.73M3.03M3.20M2.58M1.66M0.99M0.58M1.00M1.28M0.95M1.13M
Other Non Operating IncomeOther Non Op Inc.
0.01M0.28M-0.10M-0.20M-0.11M-0.27M-0.05M-0.08M0.30M-0.22M0.21M-4.12M-0.74M0.14M0.25M0.60M0.36M1.10M0.45M0.66M
Net income details
EBT
-83.27M-113.08M-35.49M-74.08M-85.01M-72.98M-81.86M-113.92M0.68M-87.89M-107.69M-46.17M-59.18M-49.21M-49.64M-94.40M-42.51M-59.92M-47.66M-64.29M
Profit After TaxPAT
-83.36M-112.02M-31.45M-72.47M-85.19M-78.36M-82.12M-114.00M1.65M-88.12M-107.47M-50.29M-59.92M-49.07M-49.39M-93.80M-42.15M-58.83M-47.21M-63.70M
Income from Continuing OperationsIncome (Continuing)
-83.27M-113.08M-35.49M-74.08M-85.01M-72.98M-81.86M-113.92M0.68M-87.89M-107.69M-46.17M-59.18M-49.21M-49.64M-94.40M-42.51M-59.92M-47.66M-64.29M
Consolidated Net IncomeConsol Net Inc.
-83.27M-113.08M-35.49M-74.08M-85.01M-72.98M-81.86M-113.92M0.68M-87.89M-107.69M-46.17M-59.18M-49.21M-49.64M-94.40M-42.51M-59.92M-47.66M-64.29M
Income towards Parent CompanyParent Net Inc
-83.27M-113.08M-35.49M-74.08M-85.01M-72.98M-81.86M-113.92M0.68M-87.89M-107.69M-46.17M-59.18M-49.21M-49.64M-94.40M-42.51M-59.92M-47.66M-64.29M
Net Income towards Common StockholdersNet Income
-83.27M-113.08M-35.49M-74.08M-85.12M-72.98M-81.86M-113.92M0.98M-87.89M-107.69M-46.17M-59.92M-49.21M-49.64M-94.40M-42.51M-59.92M-47.66M-64.29M
Additional items
EPS (Basic)
-0.46-0.68-0.19-0.39-0.45-0.39-0.43-0.590.00-0.45-0.50-0.20-0.25-0.21-0.21-0.40-0.16-0.24-0.17-0.22
EPS (Diluted)
-0.46-0.68-0.19-0.39-0.45-0.39-0.43-0.590.00-0.45-0.50-0.20-0.25-0.21-0.21-0.40-0.16-0.24-0.17-0.22
Shares Outstanding
181.83M166.43M185.96M187.63M189.30M188.34M191.23M192.54M196.98M194.54M217.29M234.44M235.41M230.89M237.58M238.41M260.49M253.23M276.86M295.67M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
181.83M166.43M185.96M187.63M189.30M188.34M191.23M192.54M200.47M194.54M217.29M234.44M235.41M230.89M237.58M238.41M260.49M253.23M276.86M295.67M
EBITDA
-83.43M-111.28M-31.68M-72.90M-86.19M-81.79M-84.05M-116.29M-2.18M-90.62M-110.72M-49.37M-61.76M-50.87M-50.63M-94.97M-43.52M-61.20M-48.61M-65.42M